从癫痫到抽动障碍——“柴胡菖钩汤”异病同治的理论探讨

From Epilepsy to Tic Disorders—Theoretical Basis of “Chaihu Changou Decoction” for Treating Different Diseases Based on Shared Pathogenesis

摘要: “异病同治”不以病名或异常运动表型相同为充分依据，而要求不同疾病在特定阶段具有可识别、可检验的共同证候结构。柴胡菖钩汤源于风痰闭窍证癫痫的辨治经验，现有材料包括原适应证临床及动物研究、方证理论与单体成分药理，尚无抽动障碍中的直接确证证据。本文采用问题导向的理论分析，按证据直接性区分方源与原适应证证据、证候与方剂内部一致性、候选生物学通路及目标疾病直接证据。本文提出，风痰闭窍证癫痫与肝亢风动兼风痰火扰证抽动障碍在证候解释层面可能共享“肝失疏泄–郁火内生–火动生风–痰随风升–脑神与筋窍失序”的病机链，但在意识状态、运动形式及病邪作用层次上呈现“同机异出”。方剂配伍与候选证候具有内部一致性；既有药理仅提示多巴胺相关动作门控、兴奋抑制及突触调节、神经炎症三条候选路径，不能确证整方抗抽动机制。为使该假说可被证伪，本文提出研究性证型操作框架、固定核心方干预与分阶段验证路径。因此，柴胡菖钩汤用于特定证型抽动障碍可作为候选假说进入探索性验证，尚不构成疗效或临床推荐结论。

Abstract: Treating different diseases with the same therapy requires more than a shared disease label or a similar motor phenotype. It requires a testable pattern-level structure that is present in different disorders at defined stages. Chaihu Changpu Gouteng Decoction was developed for epilepsy with the wind-phlegm obstructing the orifices pattern. Existing evidence comprises studies in the original indication, pattern-formula reasoning, and pharmacological findings on individual constituents, but no confirmatory evidence is available in tic disorders. This hypothesis article organizes the evidence by directness and proposes that epilepsy with wind-phlegm obstructing the orifices and tic disorders with hyperactive liver-wind accompanied by wind, phlegm, and fire may share a pattern-level chain involving impaired liver regulation, constrained fire, internal wind, ascending phlegm, and dysregulation of mental and motor functions. Their clinical outputs nevertheless differ in consciousness, motor expression, and the depth of functional disturbance. The prescription is internally consistent with the candidate pattern, whereas existing pharmacology only identifies three exploratory routes involving dopamine-related action gating, excitatory-inhibitory and synaptic regulation, and neuroinflammation. To make the hypothesis falsifiable, we propose a research-oriented pattern framework, a fixed-core-formula intervention, and a staged validation pathway. Chaihu Changpu Gouteng Decoction may therefore enter exploratory evaluation as a candidate hypothesis for a defined tic-disorder subgroup, but the present evidence does not establish efficacy, mechanism, or clinical recommendation.